Combination Drug Products' Eligibility For Patent Term Extension Is Limited, Court Says
This article was originally published in The Pink Sheet Daily
Executive Summary
At least one of the active ingredients "must be new to the marketplace," a federal appeals court says in denying a patent extension for Abbott's Vicoprofen. The ruling could have a significant impact on big pharma companies that are eyeing combo therapies as growth drivers.